logo
Plus   Neg
Share
Email

Integra LifeSciences Sees Q4 Revenue At Higher End Of Prior Guidance

Integra LifeSciences Holdings Corp. (IART) said it expects reported revenue for the fourth quarter of 2018 to be at the higher end of its previous guidance range of $378 million to $383 million. Organic revenue growth in the fourth quarter 2018 is expected to be slightly above 4%. Analysts polled by Thomson Reuters expects the company to report earnings revenues of $380.76 million for the fouth-quarter. Analysts' estimates typically exclude special items.

Integra LifeSciences also said it has signed a license and development agreement with Consortium of Focused Orthopedists, LLC, for a short stem and stemless shoulder system.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent. Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.
Follow RTT